News

AB-Therapeutics new anticancer compounds reduce by 70% lung tumors growth

The Barcelona based biotech company is in a series-A fundraising round to conduct preclinical development and to file an IND in late 2011

November 8, 2010

The Barcelona-based biotech company AB Therapeutics has obtained high efficacy results with its 2 new anticancer compounds in animal models of lung cancer (NSCLC) using Membrane Lipid Therapy (MLT), a new therapeutic approach. After 4 weeks treatment in immunosupressed mice, the molecules reduced tumor growth in treated animals by 70%. Additionally, tumor growth arrest was observed in 10% of treated mice. Adverse events were markedly lower than in mice treated with gold standard treatment docetaxel.
AB-Therapeutics is in a series-A fundraising round to conduct preclinical development and to file an IND in 3Q2011 to start phase I clinical trials in late 2011. Capital needs are 0.8-1 M€ in 2010, 2.8 M€ in 2011 and 5 M€ in 2012. The company expects to receive 2 M€ in government soft loans from European, Spanish and Catalan institutions.
 
“We are satisfied to have in vivo validation of in vitro results, not only in efficacy but also in low toxicity”, said Jordi Espadaler, PhD, VP Discovery Research. “The results obtained will allow us to build the regulatory preclinical package to start clinical trials next year. We have initiated a series A round of financing to accomplish this goal”, said Carles Domenech, PhD, CEO.
 
Dr. Domenech highlights that MLT “could represent an important contribution to human health”, and also points at its high market potential: “Our compounds have blockbuster potential due to the high mortality in lung cancer, still an unmet medical need”.
 
ABOUT MEMBRANE LIPID THERAPY
MLT is a new therapeutic approach, with a mechanism of action consisting in modifying the dynamics of cell membranes, thus altering the activity of multiple proteins involved in cell growth regulation.
 
Molecules under preclinical development selectively induce apoptosis in several cancer types: lung, pancreatic, glioma and leukemia.
 
ABOUT AB-THERAPEUTICS
 
AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
 
AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.
 
 
Contact:
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com

LATEST NEWS

18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
05.02.2014

News

ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits